AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019The effects of tenofovir on bone mineral density and vitamin D metabolism in HIV positive Chinese MSMView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019HIV-associated Neurocognitive Disorder in the Philippines: A Preliminary StudyView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Higher proportion of abnormal nutritional status among HIV-infected Asian elderly with chronic virological suppression compared to HIV-negative individualsView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Low muscle mass is the body composition parameter most predictive of pre-frailty and frailty in Asians living with HIVView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Predictive effect of Body Mass Index on Immune Reconstitution among HIV-Infected HAART Users in ChinaView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Pharmacoeconomic evaluation of JULUCA (DTG/RPV) for human immunodeficiency virus (HIV-1) infection treatment in virologically-supressed adults in Taiwan.View Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Weight-based ART regimens in adults can achieve viral suppression and save costsView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Impact of point-of-care pharmacist counseling at late refills of antiretroviral therapy: A Study Following the Early Warning Indicators of World Health Organization RecommendationsView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Raltigravir was non-superior to Lopinavir/ritonavir for treatment-experienced Chinese patients with HIV-1 infection: a 48-week randomized multicenter control studyView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Evolution of weight and lipid profiles in HIV-positive patients switched to coformulated elvitegravir/ cobicistat/emtricitabine/ tenofovir alafenamideView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019Low prevalence of HLA-B*5701 and abacavir intolerance in HLA-B*5701 negative Thais with acute HIV infectionView Abstract
AbstractHIVRSVViral Hepatitis and Liver DiseaseAPACC 2019The efficacy and safety of two-drug regimen including dolutegravir plus a boosted protease inhibitor in highly experienced HIV-infected patientsView Abstract
